ADCs are a type of cancer treatment designed to specifically and directly deliver chemotherapies to tumor cells while sparing healthy cells. The concept of ADCs is based on exploiting the high specificity of a monoclonal antibody toward a selected tumor cell-surface antigen and enhancing the cell-killing capacity of the antibody by attaching a highly cytotoxic agent. Typically, several molecules of a highly potent cytotoxic compound are linked to each antibody molecule to enhance its activity, while retaining the favorable pharmacokinetic and pharmacodynamic properties of the antibody. The key to this type of therapy is getting three distinct molecules—antibody, active drug and linker—to work together.
Unlike traditional chemotherapy that indiscriminately damages healthy cells as well as tumor cells, ADC utilizes monoclonal antibody to bind to tumor-specific antigen targets and then delivers the chemotherapy, a highly potent cytotoxic agent, to kill tumor cells. In this way, ADCs may significantly benefit cancer patients by causing less adverse effects (AEs) or severe adverse effects (SAEs).
Abbreviation: MC = maleimidocaproyl; MMAE = monomethyl auristatin E; PAB = p-aminobenzyl. Note: MC-Val-Cit-PAB is a cathepsin cleavable ADC linker.
As illustrated in the diagram above, in Disitamab Vedotin, a novel humanized HER2 antibody and monomethyl auristatin E (MMAE), a potent tubulin binder with a half maximal inhibitory concentration (IC50) in the subnanomolar range, as the cytotoxic payload, are conjugated to each other through a cathepsin cleavable linker, with optimized drug-antibody ratio. The anti-HER2 antibody allows Disitamab Vedotin to selectively deliver the anti-cancer agent MMAE to HER2-expressing tumor cells.
HER2 is a member of the epidermal growth factor receptor (EGFR) family. It is expressed in many tissues, including the breast, gastrointestinal tract, kidney and heart. Its major role in these tissues is to promote cell proliferation and suppress apoptosis. Amplification of the HER2 gene and overexpression of its product may drive excessive or uncontrolled cell growth and tumorigenesis. Our clinical data support the scientific view that the HER2 pathway may play a key role in the treatment of many cancer types with tumors that express HER2 antigen, such as breast, gastric, lung and urothelial cancers.
Disitamab Vedotin comprises a novel HER2 monoclonal antibody that targets a different epitope of, and also shows a high binding affinity for, HER2 receptors on the tumor cell. Once Disitamab Vedotin binds to its target (HER2) which is expressed on tumor cell surface, through its antibody component (disitamab), the ADC-HER2 complex is internalized by the tumor cell via endocytosis. The linker connecting antibody and cytotoxic payload is then cleaved in the presence of lysosomal protease. Once the payload, MMAE, is released into cytosol, it binds tubulin and inhibits its polymerization, which triggers apoptosis or the programmed cell death of the HER2-expressing tumor cell. MMAE, once released, also has the capacity to kill neighboring tumor cells (whether HER2-expressing or not), which is known as the bystander-killing effect. Studies have found that ADCs with highly membrane-permeable payloads, such as MMAE, have a more potent bystander killing effect than those ADCs that have low membrane-permeable payloads, indicating a higher anti-tumor potential for our Disitamab Vedotin.
RemeGen is implementing a differentiated development and commercial strategies for Disitamab Vedotin for prevalent HER2 expressing cancers lacking effective treatment methods. The indications of Disitamab Vedotin include HER2 expressing (IHC 1+ or above) cancer, such as gastric cancer (GC) and urothelial carcinoma (UC), and HER2 low-expressing cancer (IHC 2+ / FISH- or IHC 1+), such as HER2 low-expressing breast cancer.These therapeutic areas represent a less crowded but underserved field for HER2-targeted therapies, and a broad addressable patient population for Disitamab Vedotin.
•Innovative molecular design leads to improved efficacy and reduced resistance with therapeutic potential in HER2-expressing cancer indications
-Novel antibody with higher affinity for HER2 compared to standard of care
-Potent cytotoxic payload with bystander-killing effects
-Cleavable linker with no lysosomal resistance
•Strong anti-tumor activity
•Favorable safety profile